Dare Bioscience, Inc. Proceeds from Debt, Net of Issuance Costs
Dare Bioscience, Inc. (DARE) reported Proceeds from Debt, Net of Issuance Costs of $179.88 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-26.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromDebtNetOfIssuanceCosts · last filed 2026-03-26
- Dare Bioscience, Inc. proceeds from debt, net of issuance costs for fiscal 2025 was $179.88K.
- Dare Bioscience, Inc. proceeds from debt, net of issuance costs for fiscal 2024 was $0.00.
| Period end | Proceeds from Debt, Net of Issuance Costs 12 month |
|---|---|
| 2025-12-31 | $179.88K 10-K · filed 2026-03-26 |
| 2024-12-31 | $0.00 10-K · filed 2026-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |